Telomerase activity in normal and malignant mammalian tissues: feasibility of telomerase as a target for cancer chemotherapy. by Burger, A. M. et al.
British Joumal ofCancer (1997) 75(4), 516-522
© 1997 Cancer Research Campaign
Telomerase activity in normal and malignant
mammalian tissues: feasibility of telomerase as a target
for cancer chemotherapy
AM Burger, MC Bibby and JA Double
Clinical Oncology Unit, University of Bradford, Bradford BD7 1 DP, UK
Summary Telomerase, a ribonucleoprotein enzyme, has been found in immortalized but not in most somatic adult human tissues, and thus
emerged as a novel target for cancer chemotherapy. However, its usefulness could still be limited by normal tissue toxicity. This study
compares enzyme activity in tissues and tumours in conventional in vivo models and human biopsy material, specifically normal human liver,
with a view to determining the therapeutic potential of anti-telomerase therapy. The telomeric repeat amplification protocol (TRAP assay) was
used to measure enzyme activity and levels were semiquantified by assaying equal concentrations of cellular protein. Telomerase activity was
high in the murine embryonic stem cell line CGR8.8, WRL 68 human embryo liver cells, testis, ovary and liver of adult mouse and rat. Low
activity was detected in normal human liver, marmoset and pig liver. Very low enzyme activity was seen in mouse, rat and marmoset bone
marrow, brain or skin; no activity could be detected in mammalian lung and heart. On the contrary, all 30 human and murine malignant tissues
studied showed high to moderate enzyme levels. However, activity found in murine liver was often higher than in tumour, e.g. in the
transplantable adenocarcinoma of the colon MAC16. Our findings indicate that telomerase is present not only in murine but also in other
normal mammalian tissues such as liver, and that this activity might result from the presence of somatic stem cells. In view of this, the role of
telomerase as a potential selective target for therapy needs further investigation. Furthermore, the understanding of regulatory pathways of
this enzyme and the selection of screening models will be critical.
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Telomeres are protein-DNA structures at the chromosomal ends of
eukaryotic cells that allow a cell to distinguish intact from broken
chromosomes, protect from end degradation or recombination and
are substrates for novel replication mechanisms (Zakian, 1995;
Rhyu, 1995). Telomeres are usually replicated by telomerase, a
telomere-specific reverse transcriptase that adds telomeric repeats
onto chromosomal ends using a segment of its RNA component
(hTR) as atemplate (Feng etal, 1995). The vertebrate tandem repeat
sequence is TTAGGG. Progressive telomere shortening has previ-
ously been linked to cell senescence and ageing (Harley etal, 1990).
A current hypothesis proposes that activation of the nucleoprotein
enzyme telomerase is essential for cells to overcome cellular senes-
cence, and thus indefinite proliferation/immortality and malignant
progression are associated with telomerase activity (Kim etal, 1994;
Chadeneau et al, 1995a; Bednarek et al, 1995). In agreement with
this idea, telomerase activity has been detected in almost all human
cancers, including ovary, breast, prostate, colon, stomach, liver,
brain, neuroblastomas, etc. (Kim et al, 1994; Rhyu et al, 1995). So
far, in all the tumour tissues examined, 85% have telomerase
activity, but activity has been seen in only 4% of normal/adjacent
specimens. Among the normal adult human tissues examined,
telomerase activity was reported in germline cells and little activity
was seen in normal bone marrow and peripheral blood leucocytes
and lymphoid cells or epidermis of skin (Broccoli et al, 1995;
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Hiyamaet al, 1995; Tayloretal, 1996; Wrightetal. 1996). The func-
tion and presence of telomerase activity in these renewable tissues
however remains largely undefined. Telomerase has therefore
emerged as an attractive potential target for cancer chemotherapy
(Chadeneau et al, 1995b; Morin, 1995; Parkinson, 1996).
To enable testing of anti-telomerase strategies, appropriate in
vivo models need to be available to assess potential candidate
drugs for activity and to predict toxicological indices. As it seems
likely that pure/specific telomerase inhibitors will need prolonged
use, and efficacy could only be judged by monitoring telomere
length as an end point (Parkinson, 1996), the identification of
adequate tumour and in vivo systems will be critical. Chadeneau et
al (1995b) have previously studied a transgenic mouse model
overexpressing the neu gene. In this study, we investigated the
feasibility ofconventional murine transplantable tumours to assess
potential telomerase inhibitors by comparing telomerase activity
in tumour vs normal tissues. We further examined telomerase
expression in organs of a variety of mammalian species that are
critical to drug toxicity, especially liver, an organ with regenera-
tive capacity (Vandersteenhoven and Burchette, 1990; Gibson-
D'Ambroso et al, 1993).
MATERIALS AND METHODS
Tissues
Surgical specimens were flash frozen in liquid nitrogen immedi-
ately after removal and stored at -80°C. For telomerase extraction
approximately 30 mg oftissue was washed twice in ice-cold phos-
phate-buffered saline (PBS), then in telomerase washing buffer
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[(10 mm Hepes-potassium hydroxide pH 7.5, 1.5 mm magnesium
chloride, 10 mm potassium chloride, 1 mm DYT (Kim et al, 1994)]
and finally homogenized in about 250 pl oflysis buffer [10 mm Tris-
HCl pH 7.5, 1 mm magnesium chloride, 1 mm EGTA, 0.1 mM
phenylmethylsulphonylfluoride (PMSF) 5 mm 2-ME,0.5% CHAPS,
10% glycerol (Kim et al, 1994)] using a sterile glass tissue homoge-
nizer (Merck, Lutterworth, UK). Homogenates were kept on ice for
30 min and were then centrifuged at 25 000g for 30 min at 4'C
(Beckman, Optima TL Ultracentrifuge). Supernatant was carefully
removed and stored at -80°C. Total cellular protein was determined
by Bradford assay (Bradford, 1976).
CL)~~~~~~~~C
CD~~~~~~~
co m-
Human tissues
Human liver specimens were obtained from IIAM (International
Institute for the Advancement of Medicine), Leicester, UK, and
the Surgery Department of St. James's Hospital, Leeds, UK. Other
human material and human tumour samples were from Bradford
Royal Infirmary. All human samples examined in this study were
collected with the approval of an ethics committee.
NADPH-cytochrome c (P450) reductase activity was measured
as a functional liver control enzyme (Gibson and Skett, 1986).
Animal tissues
Certified pathogen-free mice and rats were supplied by B&K,
Hull, UK. Marmoset tissues were derived from an in-house
colony. The MAC transplantable adenocarcinomas of the colon
were derived from routinely passaged tumour fragments and are
described elsewhere (Double et al, 1975). All animal experiments
were conducted in compliance with a UK Home Office Licence.
Cell lines
The human skin fibroblast cell lines used, WRL 68 human embry-
onic liver cells and the WEHI 3B mouse leukaemia line were
obtained from the European Collection of Animal Cell Cultures
(Porton Down, UK). The human breast fibroblast line BTS30 and
the MAC colon carcinoma cell lines were established as reported
previously (Phillips et al, 1990; Hambly, 1994). The melanoma
cell lines SK-MEL 2 and SK-MEL 5 were provided by the NCI-
Frederick Cancer Research Tumor Repository (Frederick, MD,
USA); the mouse embryonic stem cells CGR8.8 (ES) were a gift
from Dr Bill Skarnes, Edinburgh, and the Susa CP testicular cancer
cells from Dr John Masters, London. The human hepatocytes HH-
0003 and HH-0021 were a gift from IIAM, Exton, PA, USA.
Tumour cells were routinely passaged and cultured in RPMI-
1640 medium supplemented with 10% fetal calf serum and 2 mm
L-glutamine. Fibroblast cell lines were maintained in Eagle's
minimum essential medium containing 2mM L-glutamine, 15%
fetal calf serum and 1% non-essential amino acids. Forextraction of
telomerase activity, exponentially growing cells were trypsinized,
pelleted, the pellet washed and lysed as described previously (Kim
et al, 1994) and the amount oftotal cellularprotein determined using
the Bradford method.
Protein assay
The Bio-Rad protein assay (Bio-Rad Laboratories, Munich,
Germany), based on the Bradford methodology, was used to deter-
mine protein content in cell and tissue extracts according to the
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Figure 1 Telomerase activity in tumour (T) and normal (NL) mouse cell lines
and tissues. (A) Telomerase activity is compared in 0.6 1ig of total cellular
protein per TRAP reaction of various murine tissues as indicated above
lanes. The RNAase lane represents mouse liver extract treated with RNAase
before the TRAP assay reaction. WEHI 3B, murine leukaemia cells; ES,
CGR8.8 mouse embryonic stem cells (feeder layer free). Blank is a cell lysis
buffer blank. (B) Telomerase activity in MAC murine adenocarcinomas of the
colon (T) as compared with normal adult mouse liver (NL) of different mouse
strains as indicated above lanes. Concentrations of 0.6 and 0.06 jg of
protein are assayed for each sample. MAC 15A (a) are cultured cells, MAC
15A sc are subcutaneous tumour implants
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Table 1 Telomerase activity in malignant and normal mammalian cell lines and tissues
Malignant Normal
Tissue type No. tested Telomerase activitya Tissue type No. tested Telomerase activitya
Cell lines Cell lines
Mouse Mouse
Leukaemia 1 ... Embryonic stem cells 1 ++
Plasmacytoma 1 ++ Human
Teratocarcinoma 1 ++ Liver embryo cells 1
MAC colon carcinomas 3 ++ Hepatocytes 2
Human Primary fibroblasts 5
Tumour-derived cell lines 33 ...
Tissue
Tissues Mouse (NCR-Nu, NMRI, Balb/c)
Mouse Liver 3 ++
Teratocarcinoma 1 ++ Testis 3 ++
MAC colon carcinomas Ovary 3 ++
MAC 15A ascites 1 + Heart 3
MAC 15A s.c. 1 (+) Spleen 3 (+)
MAC 16 1 + Lung 3
MAC31 1 ++ Skin 3 (+)
MAC 26 1 + Brain 3 (+)
Human Bone marrow 3 (+)
Testicular tumour 5 ... Rat
Ovarian tumour 5 + Liver 3 ++
Ovarian ascites 2 ... pig
Breast tumour 15 + Liver 1 +
Monkey
Liver 1 +
Testis 2 ...
Bone marrow 1 (+)
Human
Liver 10 +
Testis 1 ++
PBLs 3 (+)
aRelative to telomerase activity in a human (Susa CP) or murine (WEHI 3B) control tumourcell line; +++, very high; ++, high; +, low; (+), very low/weak; - not
detectable. PBLs, peripheral blood lymphocytes. No. tested relates to different cell types/individuals; however, each sample was at least assayed in triplicate.
manufacturer's instructions. For very small samples, such as
needle biopsies, the microassay version was performed. It is
important to point out that telomerase lysis buffer does not inter-
fere with the Bradford coomassie blue-based reaction, whereas the
widely used BCA protein assay (Pierce, Rockford, IL, USA)
(Piatyszek et al, 1995) shows a substantial background staining
with lysis buffer [optical density (OD) approximately 0.5 for 5 ,ul
of lysis buffer] caused by, e.g. Tris and 2-ME (according to manu-
facturer's instructions) and could therefore give a false high OD
and consequentially an over estimate ofprotein content. In view of
this the BCA method should not be used in conjunction with the
telomeric repeat amplification protocol (TRAP assay).
Telomerase activity
The conventional TRAP assay, as described by Kim et al. (1994),
was followed with minor modifications.
Multiple concentrations ranging from 6.0 to 0.006 jg of total
cellular protein for tissue and from 10 to 0.001 jg of protein for
cell lines were assayed to determine the optimum protein concen-
tration for the polymerase chain reaction (PCR) based measure-
ment of telomerase activity. Tenfold dilutions were freshly
prepared in sterile diethyl polycarbonated water just before addi-
tion to the TRAP reaction. Optimal protein concentrations for cell
lines, which just saturate the PCR reaction but do not inhibit the
Taq-DNA polymerase (Piatyszek et al, 1995) were found to be
1.0-0.1 jg for pure cell populations and 0.60.06 jig for tissues.
TRAP assay
The TS primer was used for the telomerase extension reaction,
a non-telomeric synthetic oligonucleotide with the sequence
5'-AATCCGTCGAGCAGAGTT-3', and the CX primer, 5'-CCCT-
TACCCTTACCCTTACCCTAA-3', was used as PCR primer and is
initially separated from the rest ofthe reaction mix by a wax barrier
(Ampliwax, Perkin Elmer, Branchburg, NJ, USA). To enable
autoradiographic detection 2.0 gCi of [ac-32P]dCTP (specific
activity 3000 Ci mmol-'; Amersham International, Amersham, UK)
was added to a PCR mix of 50 jil per sample [20mM Tris-HCl
pH 8.3, 1.5 mM magnesium chloride, 63 mm potassium chloride,
0.005% Tween-20, 1 mM EGTA, 50gM dNTPs, 0.1 jig of TS
primer, 1 jig of T4g32 protein, 5 jg of bovine serum albumin
(BSA), 2U Taq-DNA polymerase (Kim et al, 1994)]. In a final step
cell lysates were added to the PCR reagents and incubated for 30
min at room temperature to allow telomerase, if present, to extend
the TS oligonucleotide. After heating the samples at 90°C for 90 s,
telomerase products were amplified in 31 PCR cycles at 94°C
for 30 s, 50°C for 30 s and 72°C for 45 s.
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Figure 2 Gel showing telomerase activity in human embryc
WRL 68, a human testis vs a seminoma (sem.) specimen ar
tissues vs MAC murine tumours. T, tumour; NL, normal; ES,
cells; BM, bone marrow. For WRL 68 cells 1.0 ,g, for tissue
cellular protein was assayed
To allow comparison of telomerase activity among cell lines or
tissues, the same amounts of total cellular protein were assayed
under the same conditions. 0.1 ,ug of total cellular protein of the
Susa CP testicular cancer cell line, which gives a very prominent
and extensive ladder signal, was used as positive control for each
set of probes examined, a lysis buffer blank was used as negative
control. The whole sample (50gl) was loaded to a 10% acrylamide
non-denaturating gel and resolved by electrophoresis at 155 V for
5-6 h in 0.5 x Tris Borate EDTA buffer. Gels were developed by
autoradiography on a sensitive film (Kodak, X-omat AR). The
amplified telomerase products are of heterogeneous length and
create a ladder pattern ofbands each representing the addition of a
hexanucleotide telomeric repeat by telomerase. Authenticity ofthe
telomerase ladder signal was confirmed by assaying in parallel
RNAase-treated cell lysates (telomerase extracts were mixed 1:1
with DNAase-free RNAase 30 min before addition of cell extract
into the reaction buffer).
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T Figure 3 Telomerase activity in human fibroblasts vs melanoma cell lines
(T). Enzyme activity in 1.0 9g of total protein per reaction is depicted. 174BR,
)nic liver cell line 1184, 180BR and 84BR are skin fibroblasts (all from ECACC); BTS 30 is a
nd normal mouse breast fibroblast line and in the case of blank, only cell lysis buffer was
, embryonic stem assayed
!s 0.6 gg of
For gels containing tumourcell lines and tissues, exposure times
were about 20 h at -80°C. To detect telomerase in human liver or
assure negative signal, extended exposure times at -80°C for up
to 1 week were necessary.
The data shown are representative of at least three independent
experiments.
RESULTS
An absolute quantitative analysis oftelomerase activity is compli-
cated by the limitations inherent in the PCR-based TRAP assay
technique. In an attempt to give a general overview of the data
described in detail below, telomerase activity of various
mammalian tissues was rated relatively (visually ranked) to
enzyme activity of a high-expressing tumour control cell line and
is summarized in Table 1.
In agreement with previous publications on telomerase activity
in certain experimental mouse strains (Blasco et al, 1995;
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Figure 4 Comparison of telomerase activity in normal livers of rat, marmoset
and humans. Two protein concentrations were assayed, 0.6 and 0.06 gg. NL,
normal tissue; T, tumour. Susa CP, testicular cancer cell line represents a
positive control sample. Liv.1 and Liv.2 are normal human livers from needle
biopsies. BM, bone marrow; RNAase represents RNAase-treated rat liver
extract
Chadeneau et al, 1995b; Prowse et al, 1995) we found that telom-
erase activity was present in many somatic tissues of the three
mouse strains examined in this study, which are commonly used
for the screening of novel chemotherapeutic agents. The enzyme
was detected in NMRI, NCR-nude and BALB/c mouse liver, skin,
brain, bone marrow, ovary and testis (Figures and 2). Levels
were relatively high in germline cells and the murine embryonic
stem (ES) cell line CGR8.8 (a feeder layer-free line), if the same
total cellular protein amounts (0.6gg) were compared, whereas no
or extremely low telomerase activity was seen in heart, lung and
spleen (Figure lA). However, comparison of MAC tumours
(transplantable adenocarcinomas of the colon) and normal mouse
liver showed equal patterns of activity (Figures lB and 2). As
depicted in Figure 1B, two protein concentrations, 0.6 and 0.06 ,ug,
are assayed for each sample to enable a quantitative comparison.
Lower expression of telomerase activity was seen in MAC 16 and
particularly MAC 15A sc than in liver of NMRI mice, the mouse
strain used with the MAC colon carcinomas. Mouse leukaemia
cell line WEHI 3B however showed very high telomerase activity
(Figure lA).
Whereas human skin fibroblast cell lines appeared to have no
detectable enzyme activity, the melanoma cell lines SKMEL-2 and
SKMEL-5 (Figure 3) and all other human tumour-derived cell
lines and tissues examined in this study, did express marked
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Figure 5 Telomerase activity in normal human donor livers and primary
hepatocytes. Donor livers D 112, D 120 and D 204, were completely healthy
and functional, D 051 and D 060 had about 50% less NADPH-cytochrome c
reductase. HH 0003 and HH 0021 are terminally differentiated human
hepatocytes derived from healthy individuals. WRL 68 are human embryo
liver cells; WRL 68/CDDP, cisplatin-treated cells; PBLs, peripheral blood
lymphocytes; blank, a lysis buffer blank
enzyme levels. In line with the working hypothesis, all 30 largely
human testicular, ovarian and breast cancer tissues and 40 human
and murine tumour cell lines tested in this laboratory, were telom-
erase positive (e.g. Figure 2, Sem., represents a seminoma spec-
imen; Figure 4 Susa CP is a testicular cancer cell line).
In view of the possibility that normal human cells and tissues
might also be sensitive to potential telomerase inhibitors, we
focused here on determination of telomerase activity in healthy
human liver. Human testicular tissue and peripheral blood lympho-
cytes (PBLs) were also assayed. Telomerase activity was prominent
in male germ-cell tissue, and very low in a pool of three healthy
adult PBL samples (Figures 2 and 5). In marked contrast to the
current opinion (Kim et al, 1994; Chadeneau et al, 1995a; Piatyszek
et al, 1995; Prowse et al, 1995; Tahara et al, 1995), we were also
able to detect weak telomerase activity in human liver derived from
seven healthy transplant livers and three normal liver samples from
cancer patients (Figures 4 and 5). These rather unexpected observa-
tions prompted us to assay liver tissue from other higher
mammalian species such as rat, pig (data not shown) and monkey.
These also expressed telomerase activity (Figure 4). It appears that
the intensity of the telomerase signal decreases from mouse to rat
and monkey and in the pig to human in relation to organ size.
In an attempt to explain the observed telomerase activity in
normal primate liver, we assumed that telomerase activity results
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from few somatic stem cells as liver is an organ with regenerative
capacity and that the detected telomerase signal is only weak due
to dilution by larger numbers of terminally differentiated/mature
telomerase-negative cells. To test this hypothesis, we measured
telomerase activity in the human embryonic liver cells WRL 68
(similar to a pure stem cell population) (Figures 2 and 5), which
had high levels of enzyme expression, and in mature primary
human hepatocytes, which in contrast lacked detectable telom-
erase activity (Figure 5). The hexanucleotide ladder pattern
observed in the mammalian liver samples was RNAase sensitive
(in Figures 1 and 4 shown for rat and mouse) and in case of WRL
68 also inhibitable in cultured cells with cisplatin, a proposed
telomerase inhibitor (Burger et al, 1996) (Figure 5).
To determine whether quality and quantity of the rarely avail-
able surgical normal liver specimens could have an impact on
detecting telomerase activity, a functional liver control enzyme,
NADPH-cytochrome c (P450) reductase, was measured in each
of the tissue sample microsomal fractions. Reduced NADPH-
cytochrome c (P450) reductase levels are indicative of possible
tissue deterioration upon storage and handling (Labow et al,
1995). Donor livers D 060 and D 051 with very little telomerase
activity (Figure 5), contained less than 50% of the NADPH-
cytochrome c reductase activity seen in D 112, D 120 or D 204.
Similar observations were reported previously (Chadeneau et al,
1995a) when another replicative enzyme, DNA polymerase, was
measured in suspiciously negative liver metastases.
DISCUSSION
The data presented here show that telomerase activity is present
not only in mammalian malignant cells and tissues, but also
normal tissues, especially those of murine origin, mammalian
germline cells and mammalian liver including mouse, rat, pig,
monkey and human. As telomerase is expressed in vital mouse
tissues such as liver, brain and bone marrow at levels that are
similar to those seen in certain transplantable mouse tumours (e.g.
MAC 16), these models would be inappropriate for assessing
potential inhibitors. The current view that telomerase is a universal
and selective target for cancer chemotherapy has to be viewed
more critically as telomerase activity could play a key role not
only in malignant but some normal tissues, especially vital organs
such as liver.
Our experiments with liver, embryonic liver cells and hepato-
cytes suggest that low telomerase activity detected in functional
and healthy human transplant livers could be due to enzyme
expression in somatic stem cells. Although these normal liver
results seem to contradict most ofthe data published, some authors
reported weak telomerase activity in apparently non-cancerous
liver tissues of patients with cirrhosis and hepatitis (Tahara et al,
1995), two conditions in which human liver has been shown to be
proliferative and express 'ductular hepatocytes' and/or facultative
stem cells (Vandersteenhoven and Burchette, 1990). It is note-
worthy that the latter study used the Bradford method to determine
cellular protein and that other authors (Chadeneau et al, 1995a)
cautioned that quality ofbiopsy material might contribute to nega-
tive results of histologically normal liver samples. If telomerase
activity is present not only in tumour cells but also somatic stem
cells, the lack of detection of any telomerase activity or weak
telomerase signal, specifically in very small human specimens,
may be related to normal tissue dilution, tissue sample quality and
technical difficulties within the TRAP procedure.
The fact that telomerase activity is detected in regenerative
tissues with high proliferative needs such as germline tissue,
embryonic stem cells (shown in this study, e.g. for human liver
WRL 68 cells and mouse embryonic stem cells CGR8.8)
haematopoietic progenitor cells (Hiyama et al, 1995) and skin
epidermis (Taylor et al, 1996) confirms the stem cell theory. The
presence of somatic stem cells expressing telomerase activity
in normal human liver is further supported by the data of Gibson-
D'Ambrosio et al (1993), who found that long-term culturing
of functionally active, normal human adult liver hepatocytes
(containing precursor stem cells) was possible, but not that of
terminally differentiated hepatocytes. Concordantly, other investi-
gators proposed that the ease of successfully establishing primary
tissue cultures from mouse tissues in general and in particular
from mouse and rat hepatocytes could be explained by the consid-
erably high telomerase levels in livers of these animals (Prowse et
al, 1995). Although earlier studies had demonstrated that the
human telomerase RNA component is expressed in many adult
organs including liver, the authors were not able to detect telom-
erase activity (Avilion et al, 1995; Feng et al, 1995). Conclusive
explanations for the phenomenon were not given. Although this
could be due to suppression/negative regulation of telomerase
protein in the tissues concerned, technical limitations inherent in
the assay as discussed above cannot be ruled out.
The latter seems to be more likely as Holt et al (1996) recently
reviewed and refined the 'telomere-telomerase hypothesis of
aging and cancer' and postulated that low telomerase activity
might be found in many normal tissues. This was attributed to acti-
vated telomerase competent cells (stem cells) in regenerative
tissues with high proliferative need, in which telomere loss would
possibly prevent replenishment. The same authors propose the
presence of three different cell types, germ cells with high telom-
erase activity and telomeres maintained, stem cells with medium
activity and in which telomeres shorten, and finally normal cells
with no activity and significant telomere loss. However, they
believe that such normal stem cells remain quiescent most oftheir
life span and might therefore not be significantly effected by anti-
telomerase therapy.
Viewed from another perspective, the presence of telomerase
activity in cells that are not terminally differentiated, including
renewal tissue stem cells etc., might be vital for these cells and
impact the wider cellular regulatory pathway. Therefore treatment
with inhibitors could result in severe organ toxicity. As mouse in
particular, but also rat and even monkey or pig, seem to have
telomerase activity in critical organs with only marginal differ-
ences to levels in tumour tissues, it will be difficult to evaluate the
therapeutic potential ofnovel antagonists in these animals.
With the proposed function of telomerase, even complete
enzyme inhibition would not produce acute cell death; cell senes-
cence and subsequent cell death would result from progressive
telomere shortening during successive cell divisions. This greatly
complicates the assessment of inhibitors as potential anticancer
agents as tumours will continue to grow in size following
complete and even selective inhibition oftelomerase activity. Thus
a 'perfect' inhibitor may appear inactive in many of the currently
used experimental animal model systems. Moreover, during the
telomere shortening process tumour burden could limit the animal
life span or, considering that the difference in telomerase expres-
sion between certain tumours and normal tissues is marginal only,
the therapeutic index for anti-telomerases could prove too small
to demonstrate anti-tumour activity in a tolerated dose-response
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relationship. Therefore combination chemotherapy with standard
cytotoxic agents and novel approaches in the development of
tumour models need careful consideration if telomerase is to be a
target for cancer chemotherapy.
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